- Open
- 123.25
- High
- 126.00
- Low
- 123.25
- Close
- 123.50
- Change
- -0.60 (-0.49%)
- Volume
- 110,264
| 9 Sept 2026 | 18:00:00 | PRTC's SPTX: New Positive Phase 1 GlyphAllo Data |
| 4 Sept 2026 | 17:30:00 | Holding(s) in Company |
| 4 Sept 2026 | 07:00:03 | Notice of Results |
| 1 Sept 2026 | 07:00:14 | Total Voting Rights |
| 21 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 29 Apr 2026 | Annual Report and Accounts 2025 | |
| 19 May 2025 | Annual Report and Accounts (to 2024-12-31) |
PureTech Health PLC is a biotherapeutics company that focuses on the clinical development of therapies for severe diseases, including immunological, fibrotic, and inflammatory conditions. The company operates a hub-and-spoke model, advancing programs through Founded Entities, which are companies it has established to develop specific therapeutic candidates. PureTech generates revenue through equity interests and potential milestone payments from these entities, while also attracting external capital to support its initiatives. It operates primarily in the biotechnology sector, with a presence in Boston and the UK.
| 9 Sept 2026 | 18:00:00 | PRTC's SPTX: New Positive Phase 1 GlyphAllo Data |
| 4 Sept 2026 | 17:30:00 | Holding(s) in Company |
| 4 Sept 2026 | 07:00:03 | Notice of Results |
| 1 Sept 2026 | 07:00:14 | Total Voting Rights |
| 21 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 29 Apr 2026 | Annual Report and Accounts 2025 | |
| 19 May 2025 | Annual Report and Accounts (to 2024-12-31) |
PureTech Health PLC is a biotherapeutics company that focuses on the clinical development of therapies for severe diseases, including immunological, fibrotic, and inflammatory conditions. The company operates a hub-and-spoke model, advancing programs through Founded Entities, which are companies it has established to develop specific therapeutic candidates. PureTech generates revenue through equity interests and potential milestone payments from these entities, while also attracting external capital to support its initiatives. It operates primarily in the biotechnology sector, with a presence in Boston and the UK.
| 28 Aug 2026 |
| 07:00:03 |
| Holding(s) in Company |
| 28 Aug 2026 |
| 07:00:03 |
| Holding(s) in Company |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £454m | -0.5% | |
PRTCPuretech Health PLC | £319m | +0.2% |
| £13m | +1.2% | |
| £11m | +0.6% | |
| £10m | +0.2% | |
| £984k | -0.8% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £454m | -0.5% | |
PRTCPuretech Health PLC | £319m | +0.2% |
| £13m | +1.2% | |
| £11m | +0.6% | |
| £10m | +0.2% | |
| £984k | -0.8% |